DiscoverDaily Medical NewsFDA weighs esketamine for depression
FDA weighs esketamine for depression

FDA weighs esketamine for depression

Update: 2019-02-15
Share

Description

Contact us: podcasts@mdedge.com

  1. FDA panels back intranasal esketamine for refractory depression.
    http://bit.ly/2TOKrfp
  2. ONC aims to help doctors, patients with information sharing in proposed rule.
    http://bit.ly/2X3SVkP
  3. Survey: Health care costs unlikely to improve in 2019.
    http://bit.ly/2SwSIYJ
  4. Vaccination and antiviral treatment don't lower stroke risk after shingles.
    http://bit.ly/2tjYQVa
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

FDA weighs esketamine for depression

FDA weighs esketamine for depression

MDedge